European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F14%3AE0104317" target="_blank" >RIV/00843989:_____/14:E0104317 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61988987:17110/14:A1501CGK

Výsledek na webu

<a href="http://dx.doi.org/10.3324/haematol.2013.099358" target="_blank" >http://dx.doi.org/10.3324/haematol.2013.099358</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3324/haematol.2013.099358" target="_blank" >10.3324/haematol.2013.099358</a>

Jazyk výsledku

angličtina

Název v původním jazyce

European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma

Popis výsledku v původním jazyce

Multiple myeloma management has undergone profound changes in the past thanks to advances in our understanding of the disease biology and improvements in treatment and supportive care approaches. This article presents recommendations of the European Myeloma Network for newly diagnosed patients based on the GRADE system for level of evidence. All patients with symptomatic disease should undergo risk stratification to classify patients for International Staging System stage (level of evidence: 1A) and forcytogenetically defined high-versus standard-risk groups (2B). Novel-agent-based induction and up-front autologous stem cell transplantation in medically fit patients remains the standard of care (1A). Induction therapy should include a triple combination of bortezomib, with either adriamycin or thalidomide and dexamethasone (1A), or with cyclophosphamide and dexamethasone (2B). Currently, allogeneic stem cell transplantation may be considered for young patients with high-risk disease a

Název v anglickém jazyce

European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma

Popis výsledku anglicky

Multiple myeloma management has undergone profound changes in the past thanks to advances in our understanding of the disease biology and improvements in treatment and supportive care approaches. This article presents recommendations of the European Myeloma Network for newly diagnosed patients based on the GRADE system for level of evidence. All patients with symptomatic disease should undergo risk stratification to classify patients for International Staging System stage (level of evidence: 1A) and forcytogenetically defined high-versus standard-risk groups (2B). Novel-agent-based induction and up-front autologous stem cell transplantation in medically fit patients remains the standard of care (1A). Induction therapy should include a triple combination of bortezomib, with either adriamycin or thalidomide and dexamethasone (1A), or with cyclophosphamide and dexamethasone (2B). Currently, allogeneic stem cell transplantation may be considered for young patients with high-risk disease a

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Haematologica

ISSN

0390-6078

e-ISSN

—

Svazek periodika

99

Číslo periodika v rámci svazku

n. 2

Stát vydavatele periodika

IT - Italská republika

Počet stran výsledku

11

Strana od-do

"p. 232-242"

Kód UT WoS článku

000336253900014

EID výsledku v databázi Scopus

—